Editorji is a popular short video news and information platform based in India. It was founded in 2018 by Vikram Chandra, one of India’s leading journalists, and has risen to prominence in the digital news space in a relatively short span of time. The platform is primarily designed for mobile devices, with applications available for Android and iOS.

ABOUT US:

about us editorji

Latest Video News: Editorji provides the latest news video headlines, latest videos clip from India and the World. Get all breaking news videos on Entertainment, Business, Coronavirus, Elections, Politics and more.

Latest Video News, Breaking News, Bollywood, Political, Sports, Business News | Editorji

+91 11 4035 6666 / info@editorji.com
3rd floor, Plot B, Khasara no 360, Sultanpur, New Delhi, Delhi 110030
<a title="mail to us" href="mailto:info@editorji.com">Send Feedback</a>
<a title="Contact Us" href="mailto:info@editorji.com">Contact Us</a>

REACH US

Contact for any questions, suggestions, comments, feedback or advertisement on Editorji.com, we are always looking forward to hearing from you.

Contact Us for Feedback, Suggestions and Advertising 

Editorji content is better experienced in our app.

India is likely to clear the Oxford vaccine against Covid-19 this week. The expert committee of the Central Drugs Standard Control Organisation is likely to meet sometime this week to examine Serum Institute of India&rsquo;s emergency-use authorisation application for Oxford-AstraZeneca&rsquo;s vaccine against coronavirus disease, the Hindustan Times has reported quoting government sources. Serum Institute, which is manufacturing and testing the Oxford-AstraZeneca coronavirus vaccine in India, last week had submitted additional data to the national drugs regulator that it had sought on December 9. It is likely that Oxford-AstraZeneca vaccine candidate may be the first anti-Covid-19 vaccine to be granted emergency-use approval in India.

India likely to clear Oxford vaccine this week: report

India is likely to clear the Oxford vaccine against Covid-19 this week. The expert committee is likely to meet sometime this week to take up the approval application

India is likely to clear the Oxford vaccine against Covid-19 this week. The expert committee of the Central Drugs Standard Control Organisation is likely to meet sometime this week to examine Serum Institute of India&rsquo;s emergency-use authorisation application for Oxford-AstraZeneca&rsquo;s vaccine against coronavirus disease, the Hindustan Times has reported quoting government sources. Serum Institute, which is manufacturing and testing the Oxford-AstraZeneca coronavirus vaccine in India, last week had submitted additional data to the national drugs regulator that it had sought on December 9

India is likely to clear the Oxford vaccine against Covid-19 this week. The expert committee of the Central Drugs Standard Control Organisation is likely to meet sometime this week to examine Serum Institute of India&rsquo;s emergency-use authorisation application for Oxford-AstraZeneca&rsquo;s vaccine against coronavirus disease, the Hindustan Times has reported quoting government sources. Serum Institute, which is manufacturing and testing the Oxford-AstraZeneca coronavirus vaccine in India, last week had submitted additional data to the national drugs regulator that it had sought on December 9. It is likely that Oxford-AstraZeneca vaccine candidate may be the first anti-Covid-19 vaccine to be granted emergency-use approval in India.

Oxford vaccine India trial on hold after DGCI notice

Phase 2 of Covid-19 trials being conducted across 17 sites in India have now been paused till further instructions from the regulator.

Serum pauses COVID vaccine trials till further DGCI instructions

Phase 2 of Covid-19 trials being conducted across 17 sites in India have now been paused till further instructions. &nbsp;DCGI on Wednesday issued a show-cause notice to Serum Institute of India for not informing about AstraZeneca suspending the clinical trials of the Oxford vaccine candidate in other countries, and also for not submitting casualty analysis of the "reported serious adverse events".&nbsp;&nbsp;
Following a scathing show-cause notice from the drug regulator, the Serum Institute of India has paused trials till further instructions from the Drug Controller General of India.

oxford vaccine

Categories